New Zealand markets close in 4 hours 42 minutes

BIIB Jan 2023 415.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
4.90000.0000 (0.00%)
As of 11:17AM EST. Market open.
Full screen
Previous close4.9000
Open4.9700
Bid4.2000
Ask5.7000
Strike415.00
Expiry date2023-01-20
Day's range4.9000 - 5.5000
Contract rangeN/A
Volume169
Open interest203
  • Motley Fool

    Is Biogen a Buy?

    Over the past year, shares of Biogen (NASDAQ: BIIB) have dropped by 13.25% while the S&P 500 has climbed by 23.74%. The biotech's poor performance might come as a bit of a surprise since last year its Alzheimer's disease (AD) drug Aduhelm became the first medicine approved in the U.S. for the illness since 2003. Do the company's recent woes represent a buying opportunity or should investors stay away?

  • Zacks

    Ionis' (IONS) Partner to Begin New Huntington's Disease Study

    Ionis' (IONS) partner, Roche, is planning a new phase II study to evaluate tominersen for the treatment of Huntington's disease.

  • Motley Fool

    Is Biogen a Buy After the Latest Aduhelm Disaster?

    Biogen's (NASDAQ: BIIB) stock is taking yet another body blow since the Centers for Medicare and Medicaid Services (CMS) issued a draft ruling on Jan. 12 that the company's troubled new Alzheimer's drug, Aduhelm, wouldn't be covered by the U.S. public insurance plans except in the context of patients enrolled in clinical trials. In my view, there isn't much hope for Aduhelm's fortunes to reverse anytime soon.